

Sheet 1 of 4

Substitute Form PTO-1449  
(Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Attorney's Docket No.  
14017-004002

Application No.  
10/082,973

Information Disclosure Statement  
by Applicant  
(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant  
James S. Norris et al.

Filing Date  
February 26, 2002

Group Art Unit  
1635

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>JL</i>	AA	5,166,057	11/24/92	Palese et al.			
	AB	5,294,533	03/15/94	Lupski et al.			
	AC	5,436,330	07/25/95	Taira et al.			
	AD	5,500,357	03/19/96	Taira et al.			
	AE	5,578,473	11/26/96	Palese et al.			
	AF	5,670,488	09/23/97	Gregory et al.			
	AG	5,824,519	10/20/98	Norris et al.			
	AH	5,912,149	06/15/99	Ruiz et al.			
<i>JL</i>	AI	09/291,902		Norris et al.			04/14/99
<i>JL</i>	AJ	09/319,395		Norris et al.			06/03/99

**Foreign Patent Documents or Published Foreign Patent Applications**


Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes
<i>JL</i>	AK	0 640 688	03/01/95	EPO			
	AL	WO 90/00624	01/25/90	PCT			
	AM	WO 92/10590	06/25/92	PCT			
	AN	WO 94/03594	02/17/94	PCT			
	AO	WO 95/07923	03/23/95	PCT			
	AP	WO 97/17433	05/15/97	PCT			
	AQ	WO 97/17458	05/15/97	PCT			
	AR	WO 98/17815	04/30/98	PCT			
	AS	WO 98/17816	04/30/98	PCT			
	AT	WO 98/17817	04/30/98	PCT			
	AU	WO 98/24925	06/11/98	PCT			
<i>JL</i>	AV	WO 99/67400	12/29/99	PCT			

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document

Examiner Signature	Date Considered
<i>Janet L. Eggers Ford</i>	3-3-05

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute Disclosure Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14017-004002	Application No. 10/082,973
<b>Information Disclosure Statement by Applicant (Use several sheets if necessary)</b>		Applicant James S. Norris et al.	
		Filing Date February 26, 2002	Group Art Unit 1635
(37 CFR §1.98(b))			

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
<i>JP</i>	AW	Bassford et al., "The Primary Pathway of Protein Export in E. Coli," <u>Cell</u> , 1991, 65:789-796, 30:367-368
	AX	Bertrand et al., "Can hammerhead ribozymes be efficient tools to inactivate gene function?" <u>Nucleic Acids Resonant.</u> , 1994, 22(3):293-300
	AY	Bouche et al., "dnAG gene product, a rifampicin resistant RNA polymerase, initiates the conversion of a single stranded coliphage DNA to its duplex replicative form," <u>J. Biol. Chem.</u> , 1975, 250:5995-6001
	AZ	Branch, "A good antisense molecule is hard to find," <u>TIBS</u> , 1998, pp. 47-48
	AAA	Castanotto et al., "Antisense Catalytic RNAs as Therapeutic Agents," <u>Adv. Pharmacol.</u> , 1994, 25:289-317
	ABB	Christoffersen et al., "Ribozymes as human therapeutic agents," <u>J. Med. Chem.</u> , 1995, 38(12):2023-2037
	ACC	Clawson et al., "Focal altered compartmentation of repetitive B2 (Alu-like) sequences in rat liver following hepatocarcinogen exposure," <u>Cell Growth Differ.</u> , 1996, 7(5):635-646
	ADD	Colberre-Garapin et al., "A new dominant hybrid selective marker for higher eukaryotic cells," <u>J. Mol. Biol.</u> , 1981, 150(1):1-1
	AEE	Crooke, "Basic Principles of Antisense Therapeutics," <u>Antisense Research and Applications</u> , 1998, Springer-Verlag Press, Berlin, Heidelberg, New York, Chapter 1, p. 3
	AFF	Felgner et al., "Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure," <u>Proc. Natl. Acad. Sci. USA</u> , 1987, 84:7413
	AGG	Gewirtz et al., "Facilitating oligonucleotide delivery: helping antisense deliver on its promise," <u>Proc. Natl. Acad. Sci. USA</u> , 1996, 93:3161-3163
	AHH	Greenberg et al., "The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice," <u>Mol. Endo.</u> , 1994, 8(2):230-239
	AII	Haseloff et al., "Simple RNA enzymes with new and highly specific endoribonuclease activities," <u>Nature</u> , 1988, 334:585-591
	AJJ	Inokuchi et al., "A hammerhead ribozyme inhibits the proliferation of an RNA coliphage SP in <u>Escherichia coli</u> ," <u>J. Biol. Chem.</u> , 1994, 269(15):11361-11366
	AKK	Koizumi et al., "Design of RNA enzymes distinguishing a single base mutation in RNA," <u>Nucl. Acids Res.</u> , 1989, 17(17):7059-7071
	ALL	Lehnher et al., "Plasmid addiction genes of bacteriophage P1: doc, which causes cell death on curing of prophage, and phd, which prevents host death when prophage is retained," <u>J. Mol. Biol.</u> , 1993, 233:414-428
	AMM	Major et al., "The combination of symbolic and numerical computation for three-dimensional modeling of RNA," <u>Science</u> , 1991, 253:1255-1260
	ANN	Marians, "Replication Fork Propagation," <u>Escherichia coli and Salmonella: Cellular and Molecular Biology</u> , 2 <sup>nd</sup> Edition, Vol. 1, Neidhard (ed.), American Society for Microbiology, Washington, D.C., 1996, pp. 749-763
<i>JP</i>	AOO	Merril et al., "Long-circulating bacteriophage as antibacterial agents," <u>Proc. Natl. Acad. Sci. USA</u> , 1996, 93(8):3188-3192
<i>JP</i>	APP	Meyer et al., "Search for a putative scrapie genome in purified prion fractions reveals a paucity of nucleic acids," <u>J. Gen. Virol.</u> , 1991, 72:1031-1038

Examiner Signature	Date Considered
<i>Karen L. Bassford</i>	<i>3-3-05</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14017-004002	Application No. 10/082,973
<b>Information Disclosure Statement</b> <b>by Applicant</b> <small>(Use several sheets if necessary)</small> <small>(37 CFR §1.98(b))</small>		Applicant James S. Norris et al.		
		Filing Date February 26, 2002	Group Art Unit 1635	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AQQ	Miller et al., "Progress in transcriptionally targeted and regulatable vectors for genetic therapy," <u>Hum. Gene Ther.</u> , 1997, 8:803-815
	ARR	Nicolau et al., "Liposomes as carriers for in vivo gene transfer and expression," <u>Methods Enzymol.</u> , 1987, 149:157
	ASS	Ohkawa et al., "Activities of HIV-RNA targeter ribozymes transcribed from a 'shot-gun' type ribozyme-trimming plasmid," <u>Nucl. Acids Symp. Ser.</u> , 1992
	ATT	Ohme-Takagi, "In vivo RNA transcript-releasing plasmid possessing a universal pseudo-terminator by means of artificial ribozymes," <u>Nucl. Acids Symp. Ser.</u> , 1990, 22:49-50
	AUU	Ohta et al., "Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells," <u>Nucl. Acid Res.</u> , 1996, 24(5):938-942
	AVV	Pace and Smith, "Ribonuclease P: function and variation," <u>J. Biol. Chem.</u> , 1990, 256(7):3587-3590
	AWW	Palese et al., "Negative-strand RNA viruses: genetic engineering and applications," <u>Proc. Natl. Acad. Sci. USA</u> , 1996, 93:11354-11358
	AXX	Poulsen et al., "The gef gene from Escherichia coli is regulated at the level of translation," <u>Mol. Microbiol.</u> , 1991, 5:1639-1648
	AYY	Schmidt et al., "Regulation of Escherichia coli secA mRNA translation by a secretion-responsive element," <u>J. Bacteriol.</u> , 1991, 173(20):6605-6611
	AZZ	Schmidt and Delihas, "micF RNA is a substrate for Rnase E," <u>FEMS Microbiol. Lett.</u> , 1995, 133(3):209-213
	AAAA	Slopek et al., "Results of bacteriophage treatment of suppurative bacterial infections in the years," <u>Arch. Immunol. Ther. Exp. (Warz)</u> , 1987, 35:569-583
	ABBB	Soothill, "Treatment of experimental infections of mice with bacteriophages," <u>J. Med. Microbiol.</u> , 1992, 37(4):258-261
	ACCC	Sternberg, "Recognition and cleavage of the bacteriophage P1 packaging site (pac) II. Functional limits of pac and location of pac cleavage termini," <u>J. Mol. Biol.</u> , 1987, 194(3):469-479
	ADDD	Stull et al., "Antigene, ribozyme and aptamer nucleic acids drugs: progress and prospects," <u>Pharm. Res.</u> , 1995, 12(4):465-483
	AEEE	Sullivan et al., "Development of ribozymes for gene therapy," <u>J. Invest. Dermatol.</u> , 1994, 103:85S-95S
	AFFF	Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both in vitro in place of run-off and (G)-free transcriptions and in vivo as multi-sequences transcription vectors," <u>Nucl. Acids Res.</u> , 1991, 19(9):5125-5130
	AGGG	Taira et al., "Construction of several kinds of ribozymes their reactivities and utilities," <u>Gene Regulation, Biology of Antisense RNA and DNA</u> , pp. 35-54
	AHHH	Taira et al., "Construction of a novel artificial-ribozyme-releasing-plasmid," <u>Protein Eng.</u> , 1990, 3(8):733-737
	AIII	Templeton et al., "Improved DNA: liposome complexes for increased systemic delivery and gene expression," <u>Nature Biotechnol.</u> , 1997, 15:647-652
	AJJJ	Uhlenbeck, "A small catalytic oligoribonucleotide," <u>Nature</u> , 1987, 328(6131):59
	AKKK	Usman et al., "Design, synthesis, and function of therapeutic hammerhead ribozymes," <u>Nucl. Acids Biol.</u> , 1996, 10:243-264

Examiner Signature	Date Considered
<i>James S. Norris</i>	<i>3-3-05</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14017-004002	Application No. 10/082,973
<b>Information Disclosure Statement by Applicant (Use several sheets if necessary)</b>		Applicant James S. Norris et al.	
		Filing Date February 26, 2002	Group Art Unit 1635
(37 CFR §1.98(b))			

<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>		
Examiner Initial	Desig. ID	Document
	ALLL	Vieweg et al., "Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer," <u>Cancer Res.</u> , 1995, 55:2366-2372
	AMMM	Whitton, "Antisense Treatment of Viral Infection," <u>Adv. Virus Res.</u> , 1994, p. 44
	ANNN	Wigler et al., "Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells," <u>Cell</u> , 1977, 11:223
	AOOO	Wigler et al., "Transformation of mammalian cells with an amplifiable dominant-acting gene," <u>Proc. Natl. Acad. Sci. USA</u> , 1980, 77:3567
	APPP	Yuyama et al., "Construction of a T-RNA-embedded-ribozyme trimming plasmid," <u>Biochem. Biophys. Res. Comm.</u> , 1992, 186(3):1271-1279
	AQQQ	Zhou et al., "Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition," <u>Antisense &amp; Nucleic Acid Drug Development</u> , 1996, 6:17-24

Examiner Signature 	Date Considered 3-3-04
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	